arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2023-29-5-442-455AQDQFTarthyper-2362Research ArticleСтатьиArticlesРоль кишечной микробиоты в развитии сердечно-сосудистой патологии: фокус на метаболиты и маркеры повышенной кишечной проницаемости и воспаления кишечной стенкиRole of intestinal microbiota in the development of cardiovascular disease: focus on metabolites and markers of increased intestinal permeability and inflammation of the intestinal wallhttps://orcid.org/0000-0002-1073-3844КолесоваЕ. П.KolesovaE. P.

Колесова Екатерина Павловна — кандидат медицинских наук, ведущий научный сотрудник научно-исследовательской лаборатории популяционной генетики научно-исследовательского отдела генетических рисков и персонифицированной профилактики Научного центра мирового уровня «Центр персонализированной медицины» 

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Ekaterina P. Kolesova, Candidate of Medical Sciences, Leading Researcher at the Research Laboratory of Population Genetics of the Research Department of Genetic Risks and Personalized Prevention of the World-class Scientific Center “Center for Personalized Medicine”

2 Akkuratov street, St Petersburg, 197341 

kolesova_ep@almazovcentre.ruhttps://orcid.org/0000-0002-5601-0668БояриноваМ. А.BoyarinovaM. A.

Бояринова Мария Анатольевна — научный сотрудник научно-исследовательской лаборатории популяционной генетики научно-исследовательского отдела генетических рисков и персонифицированной профилактики Научного центра мирового уровня «Центр персонализированной медицины» 

Санкт-Петербург

Maria A. Boyarinova, MD, Researcher at the Research Laboratory of Population Genetics of the Research Department of Genetic Risks and Personalized Prevention of the World-class Scientific Center “Center for Personalized Medicine”

St Petersburg

essence_4@mail.ruhttps://orcid.org/0000-0003-2427-4148МаслянскийА. Л.MaslyanskiyA. L.

Маслянский Алексей Леонидович — доктор медицинских наук, руководитель научно-исследовательской лаборатории ревматологии и иммунопатологии ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии Санкт-Петербургского государственного университета

Санкт-Петербург

Alexey L. Maslyanskiy, Doctor of Medical Sciences, Head of the Research Laboratory of Rheumatology and Immunopathology, Almazov National Medical Research Centre, Professor, Professor of the Scientific, Clinical and Educational Center of Gastroenterology and Hepatology of the St Petersburg University

St Petersburg

esc_4@mail.ruhttps://orcid.org/0000-0002-9658-8712МалышкинК. А.MalyshkinK. A.

Малышкин Константин Алексеевич — кандидат медицинских наук, доцент кафедры клинической лабораторной медицины 

Санкт-Петербург

Konstantin A. Malyshkin, Candidate of Medical Sciences, Associate Professor of the Department of Clinical Laboratory Medicine

St Petersburg

malyshkin.konstantin@gmail.comhttps://orcid.org/0000-0003-3920-824XКибкалоС. В.KibkaloS. V.

Кибкало София Викторовна — клинический ординатор, лаборант-исследователь научно-исследовательской лаборатории эпидемиологии неинфекционных заболеваний Института сердца и сосудов 

Санкт-Петербург

Sofia V. Kibkalo, Clinical Resident, Laboratory Assistantresearcher of the Research Laboratory of Epidemiology of Noncommunicable Diseases of the Institute of Heart and Blood Vessels

St Petersburg

sonia.kibkalo@mail.ruhttps://orcid.org/0000-0003-0029-0741НовиковаН. С.NovikovaN. S.

Новикова Надежда Сергеевна — младший научный сотрудник

Санкт-Петербург

Nadezhda S. Novikova, Junior Researcher

St Petersburg

nadezhda.lavrenova.vrn@gmail.comhttps://orcid.org/0000-0002-2569-6660ЕрмоленкоЕ. И.ErmolenkoE. I.

Ермоленко Елена Игоревна — доктор медицинских наук, заведующая лабораторией персонифицированной микробной терапии научно-образовательного центра «Молекулярные основы взаимодействия микроорганизмов и человека» Научного центра мирового уровня «Центр персонализированной медицины» 

Санкт-Петербург

Elena I. Ermolenko, Doctor of Medical Sciences, Head of the Laboratory of Personalized Microbial Therapy of the Scientific and Educational Center “Molecular Foundations of Interaction between microorganisms and Humans” of the World-class Scientific Center “Center for Personalized Medicine”

St Petersburg

lermolenko1@yandex.ruhttps://orcid.org/0000-0001-5282-8764АртемовН. Н.ArtomovN. N.

Артемов Никита Николаевич — кандидат химических наук, профессор педиатрии, руководитель научно-исследовательской лаборатории популяционной генетики научно-исследовательского отдела генетических рисков и персонифицированной профилактики Научного центра мирового уровня «Центр персонализированной медицины» ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, доцент Института прикладных компьютерных наук ФГАОУ ВО НИУ ИТМО

Санкт-Петербург

Nikita N. Artemov, Candidate of Chemical Sciences, Professor of Pediatrics, Head of the Research Laboratory of Population Genetics of the Research Department of Genetic Risks and Personalized Prevention of the World-class Scientific Center “Center for Personalized Medicine”, Almazov National Medical Research Centre, Associate Professor at the Institute of Applied Computer Sciences, ITMO University

St Petersburg

artomov@broadinstitute.orghttps://orcid.org/0000-0002-5530-9772РотарьО. П.RotarO. P.

Ротарь Оксана Петровна — доктор медицинских наук, главный научный сотрудник научно-исследовательской лаборатории эпидемиологии неинфекционных заболеваний Института сердца и сосудов, заведующая научно-исследовательской лабораторией популяционной генетики научно-исследовательского отдела генетических рисков и персонифицированной профилактики Научного центра мирового уровня «Центр персонализированной медицины» 

Санкт-Петербург

Oksana P. Rotar, Doctor of Medical Sciences, Chief Researcher of the Research Laboratory of Epidemiology of Non-communicable Diseases of the Institute of Heart and Blood Vessels, Head of the Research Laboratory of Population Genetics of the Research Department of Genetic Risks and Personalized Prevention of the World-class Scientific Center “Center for Personalized Medicine”

St Petersburg

rotar.oxana@gmail.comhttps://orcid.org/0000-0001-8169-7812КонрадиА. О.KonradiA. O.

Конради Александра Олеговна — доктор медицинских наук, профессор, академик Российской академии наук, заведующая кафедрой организации, управления и экономики здравоохранения Института медицинского образования, заместитель генерального директора по научной работе ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, руководитель международной лаборатории «Системы поддержки принятия решений в медицине», директор Института трансляционной медицины ФГАОУ ВО НИУ ИТМО

Санкт-Петербург

Aleksandra O. Konradi, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, Head of the Department of Organization, Management and Economics of Healthcare of the Institute of Medical Education, Deputy Director General for Scientific Work, Almazov National Medical Research Centre, Head of the International Laboratory “Decision Support Systems in Medicine”, Director of the Institute of Translational Medicine, ITMO University

St Petersburg

konradi@almazovcentre.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр им. В. А. Алмазова» Министерства Здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр им. В. А. Алмазова» Министерства Здравоохранения Российской Федерации; Научно-клинический и образовательный центр гастроэнтерологии и гепатологии Санкт-Петербургского государственного университетаРоссияAlmazov National Medical Research Centre; Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology of the St Petersburg UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияPavlov State Medical UniversityRussian FederationФедеральное государственное бюджетное научное учреждение «Институт экспериментальной медицины»РоссияInstitute of Experimental MedicineRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр им. В. А. Алмазова» Министерства Здравоохранения Российской Федерации; Федеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский университет ИТМО»РоссияAlmazov National Medical Research Centre; ITMO UniversityRussian Federation202327092023295442455Copyright © Колесова Е.П., Бояринова М.А., Маслянский А.Л., Малышкин К.А., Кибкало С.В., Новикова Н.С., Ермоленко Е.И., Артемов Н.Н., Ротарь О.П., Конради А.О., 20232023Колесова Е.П., Бояринова М.А., Маслянский А.Л., Малышкин К.А., Кибкало С.В., Новикова Н.С., Ермоленко Е.И., Артемов Н.Н., Ротарь О.П., Конради А.О.Kolesova E.P., Boyarinova M.A., Maslyanskiy A.L., Malyshkin K.A., Kibkalo S.V., Novikova N.S., Ermolenko E.I., Artomov N.N., Rotar O.P., Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2362

В последние годы все больше исследований свидетельствуют о тесной взаимосвязи между составом и функцией микробиоты и здоровьем человека, в том числе с сердечно-сосудистыми заболеваниями (ССЗ). Повышенная проницаемость кишечника является одним из факторов, который может влиять на состояние микробиоты, а также привести к проникновению бактерий и их токсинов в кровоток, вызывая системное воспаление. Хроническое воспаление, в свою очередь, сопровождается повышенным уровнем цитокинов, которые могут вызвать повреждение эндотелия и привести к эндотелиальной дисфункции. Метаболиты некоторых бактерий могут снижать выработку молекул, регулирующих сосудистый тонус, таких как оксид азота, что может привести к вазоконстрикции и артериальной гипертензии. В обзоре уделяется внимание связи кальпротектина, зонулина, триметиламиноксида с риском возникновения ССЗ, а также освещаются возможные методы коррекции состава и функции микробиоты для профилактики ССЗ.

In recent years, an increasing number of studies have shown a close relationship between the composition and function of the microbiota and human health, including cardiovascular diseases (CVD). Increased intestinal permeability is one of the factors that can influence the state of the microbiota and also lead to the penetration of bacteria and their toxins into the bloodstream, causing systemic inflammation. Chronic inflammation, in turn, is accompanied by increased levels of cytokines, which can cause endothelial damage and lead to endothelial dysfunction. Metabolites of some bacteria can reduce the production of molecules that regulate vascular tone, such as nitric oxide, which can lead to vasoconstriction and hypertension. The review focuses on the connection between calprotectin, zonulin, and trimethylamine oxide with the risk of CVD, and also highlights possible methods for correcting the composition and function of the microbiota for the prevention of CVD.

микробиота кишечникасердечно-сосудистые заболеванияэндотелиальная дисфункцияартериальная гипертензияповышенная кишечная проницаемостьхроническое воспалениеметаболитызонулинкальпротектинтриметиламиноксидgut microbiotacardiovascular diseasesendothelial dysfunctionarterial hypertensionincreased intestinal permeabilitychronic inflammationmetaboliteszonulincalprotectintrimethylamine oxideРабота выполнена в рамках государственного задания «Создание новой технологии таргетной коррекции микробиома кишечника и разработка персонифицированного подхода в проведении первичной профилактики и лечения атеросклероза при сердечно-сосудистых заболеваниях», регистрационный номер ЕГИСУ 121031100311-0The work was carried out within the framework of the state task “Creation of a new technology for targeted correction of the intestinal microbiome and the development of a personalized approach to the primary prevention and treatment of atherosclerosis in cardiovascular diseases”, registration number EGISU 121031100311-0ReferencesРоссийский статистический ежегодник. 2021: Росстат. Стат. сб. Под ред. П.В. Малкова. М., 2021. 692 с.Russian statistical yearbook. 2021: Statistical collection/Rosstat. In Malkov PV editor. М., 2021. 692 p. In Russian.Vernon ST, Coffey S, Bhindi R, Soo Hoo SY, Nelson GI, Ward MR et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017;24(17):1824–1830. doi:10.1177/2047487317720287Vernon ST, Coffey S, Bhindi R, Soo Hoo SY, Nelson GI, Ward MR et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017;24(17):1824–1830. doi:10.1177/2047487317720287Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904. doi:10.1001/jama.290.7.898Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904. doi:10.1001/jama.290.7.898Hijová E. Benefits of biotics for cardiovascular diseases. Int J Mol Sci. 2023;24(7):6292. doi:10.3390/ijms24076292Hijová E. Benefits of biotics for cardiovascular diseases. Int J Mol Sci. 2023;24(7):6292. doi:10.3390/ijms24076292D’Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2015;451(PtA):97–102. doi:10.1016/j.cca.2015.01.003D’Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2015;451(PtA):97–102. doi:10.1016/j.cca.2015.01.003Gulshan K. Crosstalk between cholesterol, ABC transporters, and PIP2 in inflammation and atherosclerosis. Adv Exp Med Biol. 2023;1422:353–377. doi:10.1007/978-3-031-21547-613Gulshan K. Crosstalk between cholesterol, ABC transporters, and PIP2 in inflammation and atherosclerosis. Adv Exp Med Biol. 2023;1422:353–377. doi:10.1007/978-3-031-21547-613Sattar L, Memon RA, Ashfaq F, Hamdani SSQ, Rahim Vohra R, Ashraf J et al. Efficacy and safety of colchicine in prevention of secondary cardiovascular outcomes among patients with coronary vessel disease: a meta-analysis. Cureus. 2022;14(7): e26680. doi:10.7759/cureus.26680Sattar L, Memon RA, Ashfaq F, Hamdani SSQ, Rahim Vohra R, Ashraf J et al. Efficacy and safety of colchicine in prevention of secondary cardiovascular outcomes among patients with coronary vessel disease: a meta-analysis. Cureus. 2022;14(7): e26680. doi:10.7759/cureus.26680Маслянский А.Л., Пенин И.Н., Чешуина М.Д., Тришина И.Н., Новикова А.Н., Колесова Е.П. и др. Общие закономерности продукции цитокинов и хемокинов у больных диффузными заболеваниями соединительной ткани, воспалительными артропатиями и атеросклерозом. Цитокины и воспаление. 2014;13(3):9–21Maslyanskiy AL, Penin IN, Cheshuina MD, Trishina IN, Novikova AN, Kolesova EP et al. General patterns of cytokine and chemokine production in patients with diffuse connective tissue diseases, inflammatory arthropathy and atherosclerosis. Citokiny I Vospalenie = Cytokines And Inflammation. 2014;13(3):9–21. In Russian.Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. doi:10.1002/art.24092Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. doi:10.1002/art.24092Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(5):441– 448. doi:10.1097/BOR.0000000000000528Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(5):441– 448. doi:10.1097/BOR.0000000000000528Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol. 2018;25(15):1623–1631. doi:10.1177/2047487318792952Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol. 2018;25(15):1623–1631. doi:10.1177/2047487318792952Mistry P, Reitz CJ, Khatua TN, Rasouli M, Oliphant K, Young ME et al. Circadian influence on the microbiome improves heart failure outcomes. J Mol Cell Cardiol. 2020;149:54–72. doi:10.1016/j.yjmcc.2020.09.006Mistry P, Reitz CJ, Khatua TN, Rasouli M, Oliphant K, Young ME et al. Circadian influence on the microbiome improves heart failure outcomes. J Mol Cell Cardiol. 2020;149:54–72. doi:10.1016/j.yjmcc.2020.09.006Mansuri NM, Mann NK, Rizwan S, Mohamed AE, Elshafey AE, Khadka A et al. Role of gut microbiome in cardiovascular events: a systematic review. Cureus. 2022;14(12):e32465. doi:10.7759/cureus.32465Mansuri NM, Mann NK, Rizwan S, Mohamed AE, Elshafey AE, Khadka A et al. Role of gut microbiome in cardiovascular events: a systematic review. Cureus. 2022;14(12):e32465. doi:10.7759/cureus.32465Kumarapperuma H, Wang R, Little PJ, Kamato D. Mechanistic insight: linking cardiovascular complications of inflammatory bowel disease [published online ahead of print, 2023 Jan 24]. Trends Cardiovasc Med. 2023; S1050–1738(23)00004-X. doi:10.1016/j.tcm.2023.01.002Kumarapperuma H, Wang R, Little PJ, Kamato D. Mechanistic insight: linking cardiovascular complications of inflammatory bowel disease [published online ahead of print, 2023 Jan 24]. Trends Cardiovasc Med. 2023; S1050–1738(23)00004-X. doi:10.1016/j.tcm.2023.01.002Kamperidis N, Kamperidis V, Zegkos T, Kostourou I, Nikolaidou O, Arebi N et al. Atherosclerosis and inflammatory bowel disease-shared pathogenesis and implications for treatment. Angiology. 2021;72(4):303–314. doi:10.1177/0003319720974552Kamperidis N, Kamperidis V, Zegkos T, Kostourou I, Nikolaidou O, Arebi N et al. Atherosclerosis and inflammatory bowel disease-shared pathogenesis and implications for treatment. Angiology. 2021;72(4):303–314. doi:10.1177/0003319720974552Violi F, Cammisotto V, Bartimoccia S, Pignatelli P, Carnevale R, Nocella C. Gut derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nat Rev Cardiol. 2023;20(1):24–37. doi:10.1038/s41569-022-00737-2Violi F, Cammisotto V, Bartimoccia S, Pignatelli P, Carnevale R, Nocella C. Gut derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nat Rev Cardiol. 2023;20(1):24–37. doi:10.1038/s41569-022-00737-2Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–606. doi:10.1038/35079114Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–606. doi:10.1038/35079114Galluzzo S, Patti G, Dicuonzo G, Di Sciascio G, Tonini G, Ferraro E et al. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum Immunol. 2011;72(8):636–40. doi:10.1016/j.humimm.2011.04.005Galluzzo S, Patti G, Dicuonzo G, Di Sciascio G, Tonini G, Ferraro E et al. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum Immunol. 2011;72(8):636–40. doi:10.1016/j.humimm.2011.04.005Wu H, Liu P, Gong S, Liu X, Hill MA, Liu Z et al. Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study. Eur J Med Res. 2023;28(1):167. doi:10.1186/s40001-023-01128-0Wu H, Liu P, Gong S, Liu X, Hill MA, Liu Z et al. Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study. Eur J Med Res. 2023;28(1):167. doi:10.1186/s40001-023-01128-0Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021;18(23):12836. doi:10.3390/ijerph182312836Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021;18(23):12836. doi:10.3390/ijerph182312836Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38–51. doi:10.1080/15548627.2019.1635384Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38–51. doi:10.1080/15548627.2019.1635384Sircana A, De Michieli F, Parente R, Framarin L, Leone N, Berrutti M et al. Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol Res. 2019;144:390–408. doi:10.1016/j.phrs.2018.01.013Sircana A, De Michieli F, Parente R, Framarin L, Leone N, Berrutti M et al. Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol Res. 2019;144:390–408. doi:10.1016/j.phrs.2018.01.013Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond). 2018;132(6):701–718. doi:10.1042/CS20180087Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond). 2018;132(6):701–718. doi:10.1042/CS20180087Li C, Xiao P, Lin D, Zhong HJ, Zhang R, Zhao ZG et al. Risk factors for intestinal barrier impairment in patients with essential hypertension. Front Med (Lausanne). 2021;27(7):543698. doi:10.3389/fmed.2020.5436982019Li C, Xiao P, Lin D, Zhong HJ, Zhang R, Zhao ZG et al. Risk factors for intestinal barrier impairment in patients with essential hypertension. Front Med (Lausanne). 2021;27(7):543698. doi:10.3389/fmed.2020.5436982019Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar S et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2017;28(1):76–83. doi:10.1681/ASN.2015111285Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar S et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2017;28(1):76–83. doi:10.1681/ASN.2015111285Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci Lond. 2018;132(6):701–718. doi:10.1042/CS20180087.17Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci Lond. 2018;132(6):701–718. doi:10.1042/CS20180087.17Li C, Gao M, Zhang W, Chen C, Zhou F, Hu Z et al. Zonulin regulates intestinal permeability and facilitates enteric bacteria permeation in coronary artery disease. Sci Rep. 2016;29(6):29142. doi:10.1038/srep29142Li C, Gao M, Zhang W, Chen C, Zhou F, Hu Z et al. Zonulin regulates intestinal permeability and facilitates enteric bacteria permeation in coronary artery disease. Sci Rep. 2016;29(6):29142. doi:10.1038/srep29142Blöbaum L, Witkowski M, Wegner M, Lammel S, Schencke PA, Jakobs K et al. Intestinal barrier dysfunction and microbial translocation in patients with first-diagnosed atrial fibrillation. Biomedicines. 2023;11(1):176. doi:10.3390/biomedicines11010176Blöbaum L, Witkowski M, Wegner M, Lammel S, Schencke PA, Jakobs K et al. Intestinal barrier dysfunction and microbial translocation in patients with first-diagnosed atrial fibrillation. Biomedicines. 2023;11(1):176. doi:10.3390/biomedicines11010176Khaleghi S, Ju JM, Lamba A, Murray JA. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016;9(1):37–49. doi:10.1177/1756283X15616576Khaleghi S, Ju JM, Lamba A, Murray JA. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016;9(1):37–49. doi:10.1177/1756283X15616576Kruzliak P, Novák J, Novák M, Fodor GJ. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev. 2014;25(1):67–75. doi:10.1016/j.cytogfr.2014.01.005Kruzliak P, Novák J, Novák M, Fodor GJ. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev. 2014;25(1):67–75. doi:10.1016/j.cytogfr.2014.01.005Jensen LJ, Kistorp C, Bjerre M, Raymond I, Flyvbjerg A. Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19(5):999–1004. doi:10.1177/1741826711421078Jensen LJ, Kistorp C, Bjerre M, Raymond I, Flyvbjerg A. Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19(5):999–1004. doi:10.1177/1741826711421078Kunutsor SK, Flores-Guerrero JL, Kieneker LM, Nilsen T, Hidden C, Sundrehagen E et al. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Atherosclerosis. 2018;275:205–213. doi:10.1016/j.atherosclerosis.2018.06.817Kunutsor SK, Flores-Guerrero JL, Kieneker LM, Nilsen T, Hidden C, Sundrehagen E et al. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Atherosclerosis. 2018;275:205–213. doi:10.1016/j.atherosclerosis.2018.06.817Løfblad L, Hov GG, Åsberg A, Videm V. Calprotectin and CRP as biomarkers of cardiovascular disease risk in patients with chronic kidney disease: a follow-up study at 5 and 10 years. Scand J Clin Lab Invest. 2023;83(4):258–263. doi:10.1080/00365513.2023.2211779Løfblad L, Hov GG, Åsberg A, Videm V. Calprotectin and CRP as biomarkers of cardiovascular disease risk in patients with chronic kidney disease: a follow-up study at 5 and 10 years. Scand J Clin Lab Invest. 2023;83(4):258–263. doi:10.1080/00365513.2023.2211779Sreejit G, Abdel Latif A, Murphy AJ, Nagareddy PR. Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation. Pharmacol Res. 2020;161:105212. doi:10.1016/j.phrs.2020.105212Sreejit G, Abdel Latif A, Murphy AJ, Nagareddy PR. Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation. Pharmacol Res. 2020;161:105212. doi:10.1016/j.phrs.2020.105212Bai B, Cheng M, Jiang L, Xu J, Chen H, Xu Y. High neutrophil to lymphocyte ratio and its gene signatures correlate with diastolic dysfunction in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021;8:614757. doi:10.3389/fcvm.2021.614757Bai B, Cheng M, Jiang L, Xu J, Chen H, Xu Y. High neutrophil to lymphocyte ratio and its gene signatures correlate with diastolic dysfunction in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021;8:614757. doi:10.3389/fcvm.2021.614757Bai B, Xu Y, Chen H. Pathogenic roles of neutrophil-derived alarmins (S100A8/A9) in heart failure: from molecular mechanisms to therapeutic insights. Br J Pharmacol. 2023;180(5):573–588. doi:10.1111/bph.15998Bai B, Xu Y, Chen H. Pathogenic roles of neutrophil-derived alarmins (S100A8/A9) in heart failure: from molecular mechanisms to therapeutic insights. Br J Pharmacol. 2023;180(5):573–588. doi:10.1111/bph.15998Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, Peiró OM, Bonet G, Carrasquer A et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies. Nutrients. 2022;14(13):2654. doi:10.3390/nu14132654Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, Peiró OM, Bonet G, Carrasquer A et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies. Nutrients. 2022;14(13):2654. doi:10.3390/nu14132654Jing W, Huang S, Xiang P, Huang J, Yu H. Dietary precursors and cardiovascular disease: a Mendelian randomization study. Front Cardiovasc Med. 2023;10:1061119. doi:10.3389/fcvm.2023.1061119Jing W, Huang S, Xiang P, Huang J, Yu H. Dietary precursors and cardiovascular disease: a Mendelian randomization study. Front Cardiovasc Med. 2023;10:1061119. doi:10.3389/fcvm.2023.1061119Cho CE, Caudill MA. Trimethylamine-N-oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017;28(2):121–130. doi:10.1016/j.tem.2016.10.005Cho CE, Caudill MA. Trimethylamine-N-oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017;28(2):121–130. doi:10.1016/j.tem.2016.10.005Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease. Physiol Int. 2019;106(3):195–206. doi:10.1556/2060.106.2019.19Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease. Physiol Int. 2019;106(3):195–206. doi:10.1556/2060.106.2019.19Xu KY, Xia GH, Lu JQ, Chen MX, Zhen X, Wang S et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445. doi:10.1038/s41598-017-01387-yXu KY, Xia GH, Lu JQ, Chen MX, Zhen X, Wang S et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445. doi:10.1038/s41598-017-01387-yZhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi: 10.1080/0886022X.2020.1864404Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi: 10.1080/0886022X.2020.1864404Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis. Ann Med. 2023;55(1):2215542. doi:10.1080/07853890.2023.2215542Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis. Ann Med. 2023;55(1):2215542. doi:10.1080/07853890.2023.2215542Zhang W, Miikeda A, Zuckerman J, Jia X, Charugundla S, Zhou Z et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep. 2021;11(1):518. doi:10.1038/s41598-020-80063-0Zhang W, Miikeda A, Zuckerman J, Jia X, Charugundla S, Zhou Z et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep. 2021;11(1):518. doi:10.1038/s41598-020-80063-0Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut microbiota-derived TMAO: a causal factor promoting atherosclerotic cardiovascular disease? Int J Mol Sci. 2023;24(3):1940. doi:10.3390/ijms24031940Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut microbiota-derived TMAO: a causal factor promoting atherosclerotic cardiovascular disease? Int J Mol Sci. 2023;24(3):1940. doi:10.3390/ijms24031940Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. doi:10.1038/nature09922Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. doi:10.1038/nature09922Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814–824. doi:10.1093/eurheartj/ehw582Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814–824. doi:10.1093/eurheartj/ehw582Asgary S, Rastqar A, Keshvari M. Functional food and cardiovascular disease prevention and treatment: a review. J Am Coll Nutr. 2018;37(5):429–455. doi:10.1080/07315724.2017.1410867Asgary S, Rastqar A, Keshvari M. Functional food and cardiovascular disease prevention and treatment: a review. J Am Coll Nutr. 2018;37(5):429–455. doi:10.1080/07315724.2017.1410867Derkach A, Sampson J, Joseph J, Playdon MC, StolzenbergSolomon RZ. Effects of dietary sodium on metabolites: the dietary approaches to stop hypertension (DASH)—sodium feeding study. Am J Clin Nutr. 2017;106(4):1131–1141. doi:10.3945/ajcn.116.150136Derkach A, Sampson J, Joseph J, Playdon MC, StolzenbergSolomon RZ. Effects of dietary sodium on metabolites: the dietary approaches to stop hypertension (DASH)—sodium feeding study. Am J Clin Nutr. 2017;106(4):1131–1141. doi:10.3945/ajcn.116.150136Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, Perez-Caballero AI, Gomez-Delgado F et al. CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a lowfat diet on cardiovascular disease in coronary patients. Am Heart J. 2016;177:42–50. doi:10.1016/j.ahj.2016.04.011Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, Perez-Caballero AI, Gomez-Delgado F et al. CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a lowfat diet on cardiovascular disease in coronary patients. Am Heart J. 2016;177:42–50. doi:10.1016/j.ahj.2016.04.011Jovanovski E, Nguyen M, Kurahashi Y, Komishon A, Li D, Hoang Vi Thanh H et al. Are all fibres created equal with respect to lipid lowering? Comparing the effect of viscous dietary fibre to non-viscous fibre from cereal sources: a systematic review and metaanalysis of randomised controlled trials. Br J Nutr. 2022;5:1–13. doi:10.1017/S0007114522002355Jovanovski E, Nguyen M, Kurahashi Y, Komishon A, Li D, Hoang Vi Thanh H et al. Are all fibres created equal with respect to lipid lowering? Comparing the effect of viscous dietary fibre to non-viscous fibre from cereal sources: a systematic review and metaanalysis of randomised controlled trials. Br J Nutr. 2022;5:1–13. doi:10.1017/S0007114522002355Reynolds AN, Akerman A, Kumar S, Diep Pham HT, Coffey S, Mann J. Dietary fibre in hypertension and cardiovascular disease management: systematic review and meta-analyses. BMC Med. 2022;20(1):139. doi:10.1186/s12916-022-02328-xReynolds AN, Akerman A, Kumar S, Diep Pham HT, Coffey S, Mann J. Dietary fibre in hypertension and cardiovascular disease management: systematic review and meta-analyses. BMC Med. 2022;20(1):139. doi:10.1186/s12916-022-02328-xMarkowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021. doi:10.3390/nu9091021Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021. doi:10.3390/nu9091021Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system. Curr Opin Gastroenterol. 2015;31(2):153–158. doi:10.1097/MOG.0000000000000151Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system. Curr Opin Gastroenterol. 2015;31(2):153–158. doi:10.1097/MOG.0000000000000151Capuano E. The behavior of dietary fiber in the gastrointestinal tract determines its physiological effect. Crit Rev Food Sci Nutr.2017;57(16):3543–3564. doi:10.1080/10408398.2016.1180501Capuano E. The behavior of dietary fiber in the gastrointestinal tract determines its physiological effect. Crit Rev Food Sci Nutr.2017;57(16):3543–3564. doi:10.1080/10408398.2016.1180501Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151–1156. doi:10.1126/science.aao5774Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151–1156. doi:10.1126/science.aao5774Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–184. doi:10.1080/19490976.2017.1290756Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–184. doi:10.1080/19490976.2017.1290756Lordan C, Thapa D, Ross RP, Cotter PD. Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. Gut Microbes. 2020;11(1):1–20. doi:10.1080/19490976.2019.1613124Lordan C, Thapa D, Ross RP, Cotter PD. Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. Gut Microbes. 2020;11(1):1–20. doi:10.1080/19490976.2019.1613124Medina-Vera I, Sanchez-Tapia M, Noriega-López L, Granados-Portillo O, Guevara-Cruz M, Flores-López A et al. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019;45(2):122–131. doi:10.1016/j.diabet.2018.09.004Medina-Vera I, Sanchez-Tapia M, Noriega-López L, Granados-Portillo O, Guevara-Cruz M, Flores-López A et al. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019;45(2):122–131. doi:10.1016/j.diabet.2018.09.004Javanshir N, Hosseini GNG, Sadeghi M, Esmaeili R, Satarikia F, Ahmadian G et al. Evaluation of the function of probiotics, emphasizing the role of their binding to the intestinal Epithelium in the stability and their effects on the immune system. Biol Proced Online. 2021;23(1):23. doi:10.1186/s12575-021-00160-wJavanshir N, Hosseini GNG, Sadeghi M, Esmaeili R, Satarikia F, Ahmadian G et al. Evaluation of the function of probiotics, emphasizing the role of their binding to the intestinal Epithelium in the stability and their effects on the immune system. Biol Proced Online. 2021;23(1):23. doi:10.1186/s12575-021-00160-wAhmadian F, Razmpoosh E, Ejtahed HS, Javadi M, Mirmiran P, Azizi F. Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type 2 diabetes mellitus: a secondary-data analysis of a randomized doubleblind controlled trial. Diabetol Metab Syndr. 2022;14(1):52. doi:10.1186/s13098-022-00822-zAhmadian F, Razmpoosh E, Ejtahed HS, Javadi M, Mirmiran P, Azizi F. Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type 2 diabetes mellitus: a secondary-data analysis of a randomized doubleblind controlled trial. Diabetol Metab Syndr. 2022;14(1):52. doi:10.1186/s13098-022-00822-zDixon A, Robertson K, Yung A, Que M, Randall H, Wellalagodage D et al. Efficacy of probiotics in patients of cardiovascular disease risk: a systematic review and meta-analysis. Curr Hypertens Rep. 2020;22(9):74. doi:10.1007/s11906-020-01080-yDixon A, Robertson K, Yung A, Que M, Randall H, Wellalagodage D et al. Efficacy of probiotics in patients of cardiovascular disease risk: a systematic review and meta-analysis. Curr Hypertens Rep. 2020;22(9):74. doi:10.1007/s11906-020-01080-yKhalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897–903. doi:10.1161/Hypertensionaha.114.03469Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897–903. doi:10.1161/Hypertensionaha.114.03469Cicero AFG, Fogacci F, Bove M, Giovannini M, Borghi C. Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. Eur J Nutr. 2021;60(2):655–663. doi:10.1007/s00394-020-02271-8Cicero AFG, Fogacci F, Bove M, Giovannini M, Borghi C. Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. Eur J Nutr. 2021;60(2):655–663. doi:10.1007/s00394-020-02271-8Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics — a step beyond pre- and probiotics. Nutrients. 2020;12(8):2189. doi:10.3390/nu12082189Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics — a step beyond pre- and probiotics. Nutrients. 2020;12(8):2189. doi:10.3390/nu12082189Hernández MAG, Canfora EE, Jocken JWE, Blaak EE. The short-chain fatty acid acetate in body weight control and insulin sensitivity. Nutrients. 2019;11(8):1943. doi:10.3390/nu11081943Hernández MAG, Canfora EE, Jocken JWE, Blaak EE. The short-chain fatty acid acetate in body weight control and insulin sensitivity. Nutrients. 2019;11(8):1943. doi:10.3390/nu11081943Hamamah S, Gheorghita R, Lobiuc A, Sirbu IO, Covasa M. Fecal microbiota transplantation in non-communicable diseases: recent advances and protocols. Front Med. 2022;9:1060581. doi:10.3389/fmed.2022.1060581Hamamah S, Gheorghita R, Lobiuc A, Sirbu IO, Covasa M. Fecal microbiota transplantation in non-communicable diseases: recent advances and protocols. Front Med. 2022;9:1060581. doi:10.3389/fmed.2022.1060581Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X et al. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022;12(1):1152. doi:10.1038/s41598-022-05127-9Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X et al. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022;12(1):1152. doi:10.1038/s41598-022-05127-9Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716–723. doi:10.1136/gutjnl2020-323617Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716–723. doi:10.1136/gutjnl2020-323617Qiu B, Liang J, Li C. Effects of fecal microbiota transplantation in metabolic syndrome: a meta-analysis of randomized controlled trials. PLoS One. 2023;18(7):e0288718. doi:10.1371/journal.pone.0288718Qiu B, Liang J, Li C. Effects of fecal microbiota transplantation in metabolic syndrome: a meta-analysis of randomized controlled trials. PLoS One. 2023;18(7):e0288718. doi:10.1371/journal.pone.0288718Hu D, Zhao J, Zhang H, Wang G, Gu Z. Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment. Life (Basel). 2023;13(7):1488. doi:10.3390/life13071488Hu D, Zhao J, Zhang H, Wang G, Gu Z. Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment. Life (Basel). 2023;13(7):1488. doi:10.3390/life13071488Toral M, Robles-Vera I, de la Visitacion N, Romero M, Yang T, Sanchez M et al. Critical role of the interaction gut microbiota — sympathetic nervous system in the regulation of blood pressure. Front Physiol. 2019;10:231. doi:10.3389/fphys.2019.00231.96Toral M, Robles-Vera I, de la Visitacion N, Romero M, Yang T, Sanchez M et al. Critical role of the interaction gut microbiota — sympathetic nervous system in the regulation of blood pressure. Front Physiol. 2019;10:231. doi:10.3389/fphys.2019.00231.96Kim TT, Parajuli N, Sung MM, Bairwa SC, Levasseur J, Soltys CM et al. Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice. Am J Physiol Endocrinol Metab. 2018;315(4): E511–E519. doi:10.1152/ajpendo.00471.2017.97Kim TT, Parajuli N, Sung MM, Bairwa SC, Levasseur J, Soltys CM et al. Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice. Am J Physiol Endocrinol Metab. 2018;315(4): E511–E519. doi:10.1152/ajpendo.00471.2017.97

The authors declare that there are no conflicts of interest present.